Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia

DOI Web Site PubMed
  • ARAKAWA Yuki
    Department of Hematology/Oncology, Saitama Children's Medical Center
  • KOH Katsuyoshi
    Department of Hematology/Oncology, Saitama Children's Medical Center
  • AOKI Takahiro
    Department of Hematology/Oncology, Saitama Children's Medical Center
  • KUBOTA Yasuo
    Department of Hematology/Oncology, Saitama Children's Medical Center
  • OYAMA Ryo
    Department of Hematology/Oncology, Saitama Children's Medical Center
  • MORI Makiko
    Department of Hematology/Oncology, Saitama Children's Medical Center
  • HAYASHI Mayumi
    Department of Hematology/Oncology, Saitama Children's Medical Center
  • HANADA Ryoji
    Department of Hematology/Oncology, Saitama Children's Medical Center

Bibliographic Information

Other Title
  • 再発・難治小児急性リンパ性白血病に対するクロファラビン併用化学療法
  • サイハツ ・ ナンチ ショウニ キュウセイ リンパセイ ハッケツビョウ ニ タイスル クロファラビン ヘイヨウ カガク リョウホウ

Search this article

Abstract

Clofarabine, one of the key treatment agents for refractory and relapsed acute lymphoblastic leukemia (ALL), achieves a remission rate of approximately 30% with single-agent clofarabine induction chemotherapy. However, a remission rate of approximately 50% was reported with a combination chemotherapy regimen consisting of clofarabine, etoposide, and cyclophosphamide. We treated two cases with refractory and relapsed ALL with combination chemotherapy including clofarabine; one was an induction failure but the other achieved remission. Both cases developed an infectious complication (NCI-CTCAE grade 3) and body pain with infusion. Prophylactic antibiotic and opioid infusions facilitated avoiding septic shock and pain. Further investigation of such cases is required.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 55 (11), 2316-2319, 2014

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top